News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Jan 21, 2021 6:06 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Jan 20, 2021
Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jan 11, 2021
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Jan 07, 2021
Forma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of Directors
Upcoming Events
Dec 7, 2020
6:00 PM EST
Forma Therapeutics Virtual Investor Event on FT-4202 in Sickle Cell Disease
Learn more
Nov 19, 2020
Virtual SVB Leerink Oncology 1X1 Day
Learn more
Nov 18, 2020
7:55 PM GMT
Jefferies 2020 Virtual London Healthcare Conference
Learn more